Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Alnylam Pharmaceuticals, Inc.. A complete text table follows the diagram.
AMVUTTRA's rapid expansion has transformed a four-drug rare-disease portfolio into a billion-dollar quarterly product business, even as its predecessor ONPATTRO declines.
Swipe to explore
The Sankey maps reported net product revenue by medicine and geography. Collaboration and royalty revenue are excluded from the flow so the graphic can isolate the commercial RNAi portfolio; they are disclosed in annotations and metadata.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| AMVUTTRA | 1 | $890M | Up 187% year over year |
| ONPATTRO | 1 | $20.5M | Down 59% as the franchise transitions |
| GIVLAARI | 1 | $74.4M | Acute hepatic porphyria |
| OXLUMO | 1 | $51.3M | Primary hyperoxaluria type 1 |
| RNAi product revenue | 2 | $1.0B | Up 121% year over year |
| United States | 3 | $779M | 75% of product revenue |
| Europe | 3 | $166M | 16% of product revenue |
| Rest of world | 3 | $91.8M | 9% of product revenue |
| From | To | Value |
|---|---|---|
| AMVUTTRA | RNAi product revenue | $890M |
| ONPATTRO | RNAi product revenue | $20.5M |
| GIVLAARI | RNAi product revenue | $74.4M |
| OXLUMO | RNAi product revenue | $51.3M |
| RNAi product revenue | United States | $779M |
| RNAi product revenue | Europe | $166M |
| RNAi product revenue | Rest of world | $91.8M |